OVERSEA CHINESE BANKING Corp Ltd lowered its holdings in Organon & Co. (NYSE:OGN - Free Report) by 55.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,000 shares of the company's stock after selling 75,500 shares during the period. OVERSEA CHINESE BANKING Corp Ltd's holdings in Organon & Co. were worth $895,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in OGN. Barclays PLC increased its holdings in Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after purchasing an additional 84,136 shares in the last quarter. Weiss Asset Management LP acquired a new stake in shares of Organon & Co. in the third quarter valued at about $32,966,000. Cerity Partners LLC raised its holdings in shares of Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock valued at $12,766,000 after buying an additional 323,308 shares during the period. Foundry Partners LLC acquired a new position in Organon & Co. during the 3rd quarter worth approximately $7,642,000. Finally, Robeco Institutional Asset Management B.V. purchased a new position in Organon & Co. in the 4th quarter worth approximately $2,263,000. Hedge funds and other institutional investors own 77.43% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Barclays lowered their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Morgan Stanley reduced their price objective on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $20.80.
View Our Latest Stock Analysis on Organon & Co.
Organon & Co. Stock Performance
OGN stock traded down $0.05 during mid-day trading on Monday, reaching $15.35. The company had a trading volume of 3,460,000 shares, compared to its average volume of 2,409,683. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The stock has a market capitalization of $3.96 billion, a P/E ratio of 4.61, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock's 50-day simple moving average is $15.44 and its two-hundred day simple moving average is $16.41.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Research analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.
Organon & Co. Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.30%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is currently 33.63%.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Featured Stories
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
